EA029860B1 - Фармацевтическая композиция и способы лечения заболеваний мочеполовой системы - Google Patents

Фармацевтическая композиция и способы лечения заболеваний мочеполовой системы Download PDF

Info

Publication number
EA029860B1
EA029860B1 EA201300129A EA201300129A EA029860B1 EA 029860 B1 EA029860 B1 EA 029860B1 EA 201300129 A EA201300129 A EA 201300129A EA 201300129 A EA201300129 A EA 201300129A EA 029860 B1 EA029860 B1 EA 029860B1
Authority
EA
Eurasian Patent Office
Prior art keywords
bei
pro
agde
seeg
antibody
Prior art date
Application number
EA201300129A
Other languages
English (en)
Russian (ru)
Other versions
EA201300129A1 (ru
Inventor
Олег Ильич ЭПШТЕЙН
Original Assignee
Олег Ильич ЭПШТЕЙН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2010129294/15A external-priority patent/RU2542414C2/ru
Priority claimed from RU2010129295/15A external-priority patent/RU2531049C2/ru
Priority claimed from RU2011127053/15A external-priority patent/RU2565400C2/ru
Application filed by Олег Ильич ЭПШТЕЙН filed Critical Олег Ильич ЭПШТЕЙН
Publication of EA201300129A1 publication Critical patent/EA201300129A1/ru
Publication of EA029860B1 publication Critical patent/EA029860B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201300129A 2010-07-15 2011-07-15 Фармацевтическая композиция и способы лечения заболеваний мочеполовой системы EA029860B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
RU2010129294/15A RU2542414C2 (ru) 2010-07-15 2010-07-15 Лекарственное средство для лечения эректильных дисфункций и способ лечения эректильных дисфункций
RU2010129295/15A RU2531049C2 (ru) 2010-07-15 2010-07-15 Лекарственное средство для лечения заболеваний предстательной железы и способ лечения заболеваний предстательной железы
RU2011127053/15A RU2565400C2 (ru) 2011-07-01 2011-07-01 Лекарственное средство для лечения заболеваний мочеполовой системы и способ лечения заболеваний мочеполовой системы
PCT/IB2011/002417 WO2012007849A2 (en) 2010-07-15 2011-07-15 Combination pharmaceutical composition and methods of treating genitourinary system disorders

Publications (2)

Publication Number Publication Date
EA201300129A1 EA201300129A1 (ru) 2013-12-30
EA029860B1 true EA029860B1 (ru) 2018-05-31

Family

ID=44899158

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201300129A EA029860B1 (ru) 2010-07-15 2011-07-15 Фармацевтическая композиция и способы лечения заболеваний мочеполовой системы

Country Status (17)

Country Link
US (1) US20130064860A1 (https=)
EP (1) EP2593483A2 (https=)
JP (3) JP2013538791A (https=)
CN (1) CN103282384A (https=)
AU (1) AU2011278042B2 (https=)
CA (1) CA2805094A1 (https=)
DE (1) DE112011102350T5 (https=)
EA (1) EA029860B1 (https=)
ES (1) ES2425314R1 (https=)
FR (1) FR2962655A1 (https=)
GB (1) GB2495885B (https=)
IT (1) ITTO20110631A1 (https=)
MX (1) MX354187B (https=)
MY (1) MY165267A (https=)
NZ (1) NZ606775A (https=)
SG (2) SG187036A1 (https=)
WO (1) WO2012007849A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
PH12013500107A1 (en) 2010-07-15 2013-03-11 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
EP2593474A2 (en) 2010-07-15 2013-05-22 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
EA029199B1 (ru) 2010-07-21 2018-02-28 Олег Ильич Эпштейн Комбинированная фармацевтическая композиция для лечения синдрома дефицита внимания и гиперактивности и способы лечения синдрома дефицита внимания и гиперактивности
PH12013500142A1 (en) 2010-07-21 2013-03-11 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
CA2926183C (en) * 2013-10-23 2018-07-03 Gemvax & Kael Co., Ltd. Composition for treating and preventing benign prostatic hyperplasia
GB201513921D0 (en) * 2015-08-05 2015-09-23 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1547612A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing erectile dysfunction
EP1547611A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing prostate diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2197266C1 (ru) * 2001-06-01 2003-01-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения эрозивных и воспалительных заболеваний желудочно-кишечного тракта
RU2001134982A (ru) * 2001-12-26 2004-02-20 Олег Ильич Эпштейн Способ коррекции иммунного ответа и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
CA2518965C (en) 2003-03-14 2018-10-30 Nutrition Research Inc. Homeopathic formulations useful for treating pain and/or inflammmation
ATE532416T1 (de) * 2004-09-03 2011-11-15 Chr Hansen As Fermentierte milchproteine mit rezeptor-ligand und ihre verwendungen
AU2006341342B2 (en) * 2006-04-04 2010-05-20 Dong-A Pharmaceutical.Co., Ltd. Agent for the prevention and treatment of prostatic hyperplasia comprising pyrazolopyrimidinone compound
RU2438707C2 (ru) * 2006-06-06 2012-01-10 Олег Ильич Эпштейн Лекарственное средство для перорального лечения сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе, и способ получения твердой лекарственной формы для пероральной терапии сахарного диабета и других заболеваний, сопровождающихся нарушением толерантности к глюкозе
BRPI0712540A2 (pt) * 2006-06-06 2012-10-16 Oleg Iliich Epshtein agente medicinal para tratar adiposidade, diabetes, e doenças associadas com intoleráncia a glicose
EP2040756A4 (en) * 2006-07-13 2013-01-09 Mazence Inc COMPOSITION CONTAINING ACIDIC AMINO ACID CHELATE AND METAL ACCELERATING METAL ABSORPTION
JP2013532181A (ja) * 2010-07-15 2013-08-15 イリイチ・エプシテイン オレグ 組み合わせ医薬組成物及び胃腸管の機能的な疾患又は状態を治療する方法
PH12013500107A1 (en) * 2010-07-15 2013-03-11 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
EP2593477A2 (en) * 2010-07-15 2013-05-22 Oleg Iliich Epshtein Pharmaceutical compositions and methods of treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1547612A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing erectile dysfunction
EP1547611A1 (en) * 2002-08-02 2005-06-29 Oleg Iliich Epshtein Medicinal agent and method for curing prostate diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
E. S. ZHAVBERT, M. V. KACHANOVA, S. A. TARASOV, YU. L. DUGINA, S. A. SERGEEVA, P. YA. DOVGALEVSKII, O. I. EPSHTEIN: "Evaluation of the Efficiency and Safety of Combined Treatment with Impaza and Nitrates in CHD Patients with Erectile Dysfunction", BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, CONSULTANTS BUREAU., vol. 148, no. 2, 1 August 2009 (2009-08-01), pages 325 - 327, XP055017424, ISSN: 00074888, DOI: 10.1007/s10517-009-0688-7 *
JONAS WAYNE B ET AL: "A critical overview of homeopathy.", ANNALS OF INTERNAL MEDICINE, AMERICAN COLLEGE OF PHYSICIANS, NEW YORK, NY; US, vol. 138, no. 5, 4 March 2003 (2003-03-04), NEW YORK, NY; US, pages 393 - 399, XP002355318, ISSN: 0003-4819 *
SHANG, A. ; HUWILER-MUNTENER, K. ; NARTEY, L. ; JUNI, P. ; DORIG, S. ; STERNE, J.A. ; PEWSNER, D. ; EGGER, M.: "Are the clinical effects of homoeopathy placebo effects? Comparative study of placebo-controlled trials of homoeopathy and allopathy", THE LANCET (LETTERS TO THE EDITOR), THE LANCET PUBLISHING GROUP, GB, vol. 366, no. 9487, 27 August 2005 (2005-08-27), GB, pages 726 - 732, XP025277623, ISSN: 0140-6736, DOI: 10.1016/S0140-6736(05)67177-2 *
VICKERS A J: "CLINICAL TRIALS OF HOMEOPATHY AND PLACEBO: ANALYSIS OF A SCIENTIFIC DEBATE", JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE, MARY ANN LIEBERT, NEW YORK, NY,, US, vol. 06, no. 01, 1 February 2000 (2000-02-01), US, pages 49 - 56, XP008055722, ISSN: 1075-5535 *

Also Published As

Publication number Publication date
EP2593483A2 (en) 2013-05-22
ITTO20110631A1 (it) 2012-01-16
SG187036A1 (en) 2013-02-28
WO2012007849A2 (en) 2012-01-19
ES2425314A2 (es) 2013-10-14
DE112011102350T5 (de) 2013-04-18
JP2018150322A (ja) 2018-09-27
MY165267A (en) 2018-03-15
GB2495885A (en) 2013-04-24
JP2016199570A (ja) 2016-12-01
EA201300129A1 (ru) 2013-12-30
MX354187B (es) 2018-02-16
SG10201505564VA (en) 2015-09-29
NZ606775A (en) 2015-08-28
GB201302651D0 (en) 2013-04-03
CA2805094A1 (en) 2012-01-19
WO2012007849A3 (en) 2012-04-05
GB2495885B (en) 2017-11-22
US20130064860A1 (en) 2013-03-14
AU2011278042B2 (en) 2017-02-16
FR2962655A1 (fr) 2012-01-20
ES2425314R1 (es) 2014-07-09
MX2013000547A (es) 2014-04-14
JP2013538791A (ja) 2013-10-17
AU2011278042A1 (en) 2013-03-07
CN103282384A (zh) 2013-09-04

Similar Documents

Publication Publication Date Title
EA029860B1 (ru) Фармацевтическая композиция и способы лечения заболеваний мочеполовой системы
ES2445846A2 (es) Una composición de combinación farmacéutica y su uso para preparar un medicamento destinado al tatamiento de la diabetes de tipo l y los trastornos metabólicos
EA030542B1 (ru) Комбинированная фармацевтическая композиция и способ лечения заболеваний или состояний желудочно-кишечного тракта функциональной этиологии
Goodman et al. Concise review: The challenges and opportunities of employing mesenchymal stromal cells in the treatment of acute pancreatitis
AU2011224341B2 (en) Modulating aquaporins with relaxin
Ma et al. The glucagon-like peptide-1 (GLP-1) analog exenatide ameliorates intrauterine adhesions in mice
KR20150109386A (ko) 뒤시엔느 근위축증의 치료에서의 항-Flt-1 항체
WO2021037292A2 (zh) 一种多肽及其应用
WO2024193322A1 (zh) 利培酮在治疗器官纤维化中的应用
JP4812748B2 (ja) 自己免疫性疾患および炎症性疾患を処置する方法
RU2159631C1 (ru) Способ остановки кровотечения из гастродуоденальных язв
CN104013974A (zh) 肝细胞生长因子基因在制备用于预防和/或治疗疼痛药物中的应用
Berlanga Heberprot-P: antecedentes experimentales y bases farmacológicas
WO2024193321A1 (zh) Glyt1抑制剂在治疗器官纤维化中的应用
CN101879151A (zh) 大黄素在制备p2x3介导神经病理痛/神经系统疾病药物中的应用
CN118490681B (zh) 瑞香素在制备治疗淋巴回流障碍的药物中的应用
JP2021535896A (ja) 気管支肺異形成症の治療における抗Ｆｌｔ−１抗体
CN115721719B (zh) Trpm8激活剂和pde5抑制剂治疗肺高压的应用
RU2170052C2 (ru) Способ оценки состояния экзосекреторной функции дистальной культи поджелудочной железы после медиальной резекции
Berlanga Heberprot-P: experimental background and pharmacological bases
Asensio et al. ZFP-36 proteins in monocyte and macrophage inflammatory signaling and differentiation. Model-ling their post-translational modifications, intracellular locations, interactome, structural hetero-geneity and halflife
Honkanen Methods of spinal cord protection in aortic surgery: experimental porcine studies
CN118846108A (zh) 多肽dp9与载体蛋白的偶联物在制备药物中的应用
CN120131939A (zh) 地舒单抗在制备抗股骨头坏死药物中的应用
CN117045628A (zh) 一种生物碱类化合物在防治腹主动脉瘤中的研究及应用

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KZ RU